Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :28328834
Publication Date : //

Varying postresection lactate dehydrogenase with overall survival of early stage pancreatic cancer patients: A retrospective study.


Several previously published studies revealed a hazardous role of pretreatment lactate dehydrogenase (LDH) in survival of advanced or metastatic pancreatic cancer (PC) patients. Nevertheless, in early stage PC patients who are eligible for curative resection, the prognostic role of postresection LDH has never been discussed. In this study, we aimed to explore the prognostic significance of varying postresection LDH among early stage PC patients. In total, 80 PC patients who received curative resection were retrospectively selected from a population-based electronic inpatients database which originated from Shanghai, China. A dynamic survival analysis method, counting process approach in combination with the multiple failure-time Cox model, was applied to evaluate the association between postresection LDH and OS. The multiple failure-time Cox model found that age, resection modality, and postresection LDH were significantly associated with OS: an elevated LDH (defined as > 250 U/L) was related to 2.93 (95% CI: 1.26-6.79) folds of death hazard. Further analysis disclosed an identifiable dose-response association between LDH and OS: compared with LDH≤155 U/L, the HRs for 155 U/L < LDH < 196 U/L, and LDH≥196 U/L were 2.07 (95% CI: 0.88-4.88) and 3.15 (95% CI: 1.30-7.59), respectively. Our study results suggest that postresection LDH is a prominent prognostic factor in this group of early stage PC patients. Maintaining normally ranged LDH after resection might bring about survival benefit in early stage PC patients.

Authors : Xiao Yuanyuan , Xie Zhihui , Shao Zhenyi , Chen Wen , Xie Hua , Qin Guoyou , Zhao Naiqing ,

Related products :

Catalog number Product name Quantity
PA1921 Mid_advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores
PA1921 Mid-advanced stage pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases_192 cores; ihc Anti-Actin confirmed
1442 Pancreatic cancer tissue array with normal pancreatic tissue, including TNM, clinical stage and pathology grade, 96 cases_96 cores, replacing PA961
T143 Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores
PA961a Pancreatic cancer tissue array with normal pancreatic tissue, including TNM, clinical stage and pathology grade, 96 cases_96 cores, replacing PA961; ihc Anti-Actin confirmed
T143 Pancreatic cancer test tissue array, with normal pancreatic tissue as control, including TNM, clinical stage and pathology grade, 2 serial sections, 6 cases_24 cores; ihc Anti-Actin confirmed
30-896 Lactate dehydrogenase C catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. LDHC is testis-specific and belongs to the lactate dehydrogenase f 0.05 mg
LC951 Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores
OV951 Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores,
CO951 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores
PA804 Pancreatic cancer and normal tissue array, with stage and grade info, 80 cases_80 cores
PA2082 High_density pancreatic cancer and normal tissue array, with stage and grade info, 101 cases_208 cores
PA481 Multiple pancreatic cancer with 4 normal tissues control from autopsy, 24 cases_48 cores, with grade and stage
KD951 Kidney cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage, pathology grade and survival data, 32 cases_95 cores
BR952 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores
LC951 Lung cancer tissue array with normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 40 cases_95 cores; ihc Anti-Cytokeratin (CK) confirmed
PA961 Pancreatic cancer and normal tissue array, including TNM, clinical stage and pathology grade, 96 cases_96 cores
OV951 Ovary cancer tissue array with matched normal adjacent tissue and metastatic carcinoma, with TNM, clinical stage and survival data, 38 cases_95 cores,; ihc Anti-Actin confirmed
CO951 Colon cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and survival data, 30 cases_95 cores, to be replaced by CO952; ihc Anti-Cytokeratin (C
BR951 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, to be replaced by BR95
BR953 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR952
BR954 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replacing BR953; ihc
BR953 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR954; ihc
BR951 Breast cancer tissue array with matched normal adjacent and metastatic carcinoma tissue, with TNM, clinical stage and ER_PR_p53 IHC results and survival data, 31 cases_95 cores, replaced by BR952; ihc
1436 Pancreatitis and matched pancreatic cancer tissue array, including TNM, clinical stage and pathology grade, 43 cases_48 cores


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur | Gentaur





GENTAUR Ltd.
Unicorn House, Station Cl
Hertfordshire, Potters Bar EN6 1TL
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017
RIB 30004 00187 00010092253 10
BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG
IBAN FR76 3000 4001 8700 0100 9225 310
france@gentaur.com | Gentaur | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur | Gentaur